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Summary The optimal schedule for recombinant interleukin-2 (rIL-2) administration is unclear. Because the
clinical and immunological effects of prolonged continuous exposure to rIL-2 are unknown, we have con-
ducted a phase I study to assess the toxicity and feasibility of continous low dose infusion of rIL-2
(EuroCetus) using central venous access with a portable infusion device on an out-patient basis. Twenty-two
patients entered the study, 13 with melanoma and nine with renal cell cancer, age range 26-66 years (median
51), performance status < 1. They were treated with one of the following doses per m2 per 24 h: 0.18 x 106 IU,
0.6 x 106 IU, 1.8 x 106 IU, 3 x 106 IU, 6 x 106 IU and 9 x 106IU. Toxicity was evaluable in 20 patients
receiving >3 weeks treatment duration or in whom treatment was discontinued prematurely because of
toxicity. Constitutional symptoms consisting of fatigue, malaise and fever up to 40°C without significant organ
dysfunction occurred with doses > 1.8 x 106 IU m-2. The maximum tolerated dose was 6 x 106 IU m-2
24 h-'. In all patients toxicity reached a peak at 3 weeks and resolved thereafter despite continued rIL-2
treatment. Peripheral blood eosinophilia (up to 66% of white blood cell count) followed the same pattern. An
infection of the central venous access occurred in 55% of the patients but this was mostly asymptomatic.
Thirteen patients were treated >6 weeks and were evaluable for tumour response. A partial remission
occurred in a patient with melanoma with a dose of 1.8 x 106 IU rIL-2 m-2 24 h-'.
The lymphokine interleukin-2 displays a wide range of effects
on the immune system. Administration of high-dose E. coli
-derived recombinant interleukin-2 (rIL-2) as a bolus injec-
tion or by continuous infusion may yield remissions in up to
25% of patients with advanced malignant disease, especially
malignant melanoma and renal cell cancer (Rosenberg et al.,
1987; Negrier et al., 1989). This relatively modest response
rate is achieved at the cost of considerable toxicity (Siegel et
al., 1991). In an attempt to increase the therapeutic index of
rIL-2, a large number of schedules with a variety of dose
levels and routes of administration have been explored, and
rIL-2 has been combined with in vitro expanded lymphokine
activated killer (LAK) cells or tumour infitrating lympho-
cytes, other cytokines, monoclonal antibodies, and various
cytostatic and immunomodulating agents (Rosenberg et al.,
1989; Truitt et al., 1989; West et al., 1987; Winkelhake et al.,
1990). All these manipulations may influence the biological
effects of rIL-2, but have not signifcantly improved the thera-
peutic index.
Treatment with rIL-2 is associated with dose-dependent
changes in the immune system. Administration of high-dose
rIL-2 may result in significant shifts in lymphocyte (sub)pop-
ulations, the in vivo generation of cells with LAK activity,
and enhancement of natural killer (NK) cell activity (Winkel-
hake et al., 1990). Clinical and experimental data show that
antibody-dependent cellular cytotoxicity (ADCC) and the
number of activated cytotoxic (CD8+) T lymphocytes (CTL)
may be increased after administration of relatively low and
less toxic doses of rIL-2 (Hank et al., 1990; Munn et al.,
1987; Naito et al., 1988; Talmadge et al., 1987). These HLA
class I restricted tumour-specific CTL's are capable of com-
pletely eradicating tumours in a variety of experimental
murine models and are considered to play an important role
in the cellular immunity in human metastatic melanoma
(Melief, 1991).
The mechanism(s) of the anti-tumour effect of rIL-2 and
the optimal means of administration are unknown. No con-
sistent correlation has been found between the biological
effects of rIL-2 and its therapeutic efficacy (Ghosh et al.,
1989; Kohler et al., 1989b). Although most tumour remis-
sions have been reported after treatment with high-dose rIL-
2, objective anti-tumour activity has also been observed with
low-dose schedules (Marumo et al., 1989; Stein et al., 1991).
These observations and extrapolation from experience with
other cytokines such as interferon-y (Kirkwood et al., 1990)
would suggest that the best immuno-modulating dose of
rIL-2 is not necessarily equivalent to the maximal tolerated
dose. The maximal tolerated dose of rIL-2 has been estab-
lished in phase I studies exploring a wide range (four logs) of
dose levels in various schedules (Creekmore et al., 1989;
Kohler et al., 1989a). These studies and preclinical models
have stressed the role of prolonged elevated serum levels of
IL-2 in the stimulation of the immune system (Cheever et al.,
1985; Thompson et al., 1988). The serum half-life of rIL-2 is
short and continuous infusion or multiple subcutaneous
injections are needed to obtain stable serum levels (Thomp-
son et al., 1987). In most reported studies, the period of
continuous infusion is 7 days or less, so it is unknown
whether prolonged rIL-2 exposure leads to persistent immune
stimulation with subsequent improved anti-tumour effect.
Between May 1989 and December 1990, we conducted a
phase I study to define the feasibility, toxicity and immuno-
logical effects of prolonged continuous infusion of rIL-2 at
various doses given on an out-patient basis. In this paper we
describe the clinical results of this study. The immunological
aspects will be discussed in detail elsewhere.
Materials and methods
Patient selection
Eligible patients (> 18 years old) had progressive, measurable
or evaluable, histologically-proven metastatic renal cell cancer
or malignant melanoma, good clinical condition (performance
status < 1) with a life expectancy of >3 months, normal bone
marrow (leucocytes >4,000 gIl-', platelets >100,000 gil-1),
renal (creatinine A 1.5 mg dl-' or calculated creatinine
clearance >60 ml min 1) and hepatic (bilirubin and alkaline
phosphatase .1.5 x upper unit of normal) function, and
normal electrocardiogram without clinical signs of cardiac or
pulmonary dysfunction. Patients with brain metastases on
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CT scan were excluded from the study. Prior radiotherapy
(except radiation to a limited area e.g. a painful bone metas-
tasis or localised lymphnode) or chemotherapy within 4
weeks (6 weeks for nitrosoureas or mitomycin C) of study
were not allowed and patients were required to have fully
recovered from previous therapies. Written informed consent
was obtained in accordance with the Netherlands Cancer
Institute guidelines. The protocol was approved by the Insti-
tute's Ethical Committee.
Interleukin 2
The E. coli-expressed recombinant rIL-2 was purchased from
EuroCetus (Amsterdam, The Netherlands). Unlike human
IL-2, EuroCetus rIL-2 is non-glycosylated. The N-terminal
alanine is deleted and at position 125 cysteine has been
replaced by serine, rIL-2 is provided as lyophilised powder
containing 0.2 mg sodium dodecyl sulphate and 50 mg man-
nitol per 3 x 106 Units (= 18 x 106 International Units (IU)).
[See Note at end of paper].
The rIL-2 was reconstituted as previously described with
1.2 ml sterile water and diluted in sterile water containing 2%
human serum albumin until the required rIL-2 concentration
had been achieved (Vlasveld et al., 1990). The solution was
aseptically prepared by the Pharmacy department and
delivered in 12 ml plastic syringes (Monoject, Sherwood, St
Louis, USA) which were stored at -20°C for a maximum of
7 days until use.
Infusion device
Central venous access was obtained via a Vascuport (Viggo,
Leusden, The Netherlands) consisting of an implantable
titanium injection portal with an 11.5 mm thick silicone
membrane and a polyurethane catheter of variable length
(inner diameter 1.20mm). The Perfusor M (Braun, Uden,
The Netherlands) was used as a portable pump; this device
empties a 10 ml syringe in 24 h. The pump and the Vascuport
were connected by a 200-300cm long polyethylene catheter
with an inner diameter of 1.5 mm (Lectro-cath) (Vygon,
Veenedaal, the Netherlands).
Study design
The study was designed to define the feasibility, toxicity, and
immunomodulatory effects of continuous infusion of rIL-2
given on an out-patient basis. Within a fortnight before entry
to the study a history and full physical examination and the
following investigations were performed, complete blood
count with differential, an extensive chemistry profile, urina-
lysis, electrocardiogram, chest radiograph, and appropriate
radiologic studies to evaluate the presence of measurable
disease. The central venous catheter was inserted under
general anaesthesia. Treatment with rIL-2 was started within
1 week of this operation. After discharge from the hospital
the patient was seen weekly at the out-patient clinic. During
treatment, clinically accessible lesions were measured and
chest X ray repeated at 3 weekly intervals. Computed tomo-
graphy or ultrasound scans were repeated every 6 weeks.
Before, every 3 weeks during treatment, and 2-4 weeks after
treatment, 30 ml peripheral blood was taken, the lympho-
cytes were isolated by centrifugation over Ficoll, and then
stored in liquid nitrogen. When possible, weekly blood cul-
tures were taken from the central venous catheter.
Recombinant IL-2 was infused continuously for 24 h a
day, 7 days a week. The syringe containing the daily-dosage
of rIL-2 was thawed at room temperature and then placed in
the perfusor pump by the patient using aseptic technique.
The six dose levels 0.18 x 106, 0.6 x 106, 1.8 x 106, 3 x 106,
6 x 106 and 9 X 106 IU m-224 h-' were tested to define tox-
icity. Patients were considered evaluable for toxicity, if rIL-2
had been continuously administered for 3 weeks or if the
treatment was prematurely discontinued because of toxicity.
At least three evaluable patients were entered at each dose
level. Because the three highest dose levels were mainly
explored to determine the maximal tolerated dose, intra-
patient dose escalation was permitted in those patients. In
addition, the four dose levels 0.18 x 106, 0.6 x 106, 1.8 x 106
and 6 x 106 IU m 2 24 h-' were explored for immunological
effects. Patients were considered evaluable for immunomodu-
latory effects providing they had received the rIL-2 con-
tinuously for a period of 6 weeks without any interruption.
In this group of patients intrapatient dose escalation, pre-
vious rIL-2 treatment or concomitant administration of non-
steroidal anti-inflammatory drugs were not allowed.
Response criteria
A complete response was defined as the complete disappear-
ance of all objective evidence of disease for a minimum of 4
weeks. A partial response was defined as a decrease of
> 50% in the sum of the product of the longest perpen-
dicular diameter of all measured lesions, no progression of
evaluable disease, and no new lesions for at least 4 weeks.
Progressive disease was defined as an increase of 25% of
measured lesions, or the development of new lesions. Lesions,
that had been irradiated within 4 weeks before entry of the
study were not evaluable for response. Patients were evalu-
ated for response at 3-6 week intervals and response dura-
tion was calculated from the date of the initial response.
Toxicity
Toxicity was scored weekly according to the World Health
Organization (WHO) criteria. For the side-effects for which
no standard WHO toxicity criteria are available the following
scoring system was used: for malaise and fatigue: grade
I = mild, no impairment of daily activity; grade 2 = moder-
ate impairment of daily activity; grade 3 = severe, <50%
bedridden during waking hours; grade 4 = intolerable, > 50%
bedridden during waking hours: For myalgia/arthalgia: grade
1 = mild, no use of analgesics; grade 2 = moderate, occasion-
al use of analgesics; grade 3 = severe, constant use of angle-
sics; grade 4 = intolerable, bedridden and constant use of
analgesics. Anaemia was defined as the decrease of the hae-
moglobin level (mmol 1') in comparison with the pretreat-
ment level: grade 1 = decrease of 1-2 mmol 1'; grade 2=
decrease 2-3 mmol l-l; grade 3 = decrease of 3-4 mmol 1;
grade 4= decrease of >4 mmol -'.
The maximum tolerable dose was defined as the dose
below that dose at which more than one third of the patients
treated experienced dose limiting toxicity. Because the treat-
ment was designed as an out-patient therapy, any toxicity
k grade 3 was considered dose limiting.
Supportive care
Paracetamol was given at a maximum dose of 6 x 500 mg to
relieve constitutional symptoms. Nausea and vomiting were
treated with metoclopramide 10-20 mg. The use of prosta-
glandin-inhibitors was avoided in the patients who were
evaluated for immunomodulatory effects.
Statistical analysis
The results were compared using the Student t-test of paired
samples. A P value of <0.05 was considered statistically
significant.
Results
Patients characteristics
Twenty-two patients entered the study. The patient charac-
teristics are summarised in Table I. A total of 30 cycles (i.e.
period of continuous rIL-2 administration) were administered
in these 22 patients as indicated in Table II. Fifteen patients
received only one cycle. Treatment was stopped in these
patients because of tumour progression (12), toxicity (one),
CVA infection (one) and patient refusal (one). Seven patients746 L.T. VLASVELD et al.
received a total of 15 separate cycles. Treatment was stopped
prematurely (<3 weeks) in ten of these cycles because toxi-
city (four), CVA infection (four) and early tumour progres-
sion (two). In four patients the dose was escalated, in three
cases from 3 x 106 to 6 x 106 IU m-2 (in two patients after 3
weeks and in one patient after 7 weeks) and in one patient
after 10 weeks at 6 x 106 IU m-2 the dose was escalated to
9 x 106 IU m-2 24 h-'.
Table I Patients characteristics
Sex
Male
Female
Age
median
range
Performance
0
1
12
10
51
26-66
19
3
Diagnosis
melanoma 13
renal cell cancer 9
Pretreatmenta
surgery 20 (nephrectomy 8)
radiotherapy 6
chemotherapy 3
melphalan limb perfusion 3
none 2
Interval since initial diagnosis (months)
median 34
range 2-168
Interval since last treatment (weeks)'
median 10.5
range 1-156
Tumour sites
cutaneous 3
pulmonary 9
lymphnode 6
bone 4
hepatic 3
miscellaneous 5
'In total three patients were treated <4 weeks prior to entry ofthe
study.Nephrectomy wasperformed in onepatientandin twopatients a
(sub)cutaneous metastasis was removed.
Table II Characteristics of 30 administered cycles of rIL-2 in 22
patients
Duration <3 weeks 10
Dose levels (IU m-2)
3 x 106 3
6 x 106 5
9 x 106 2
Reason for discontinuation
CVA infection 4
Toxicity 4
Early progression 2
Duration 3-6 weeks 3
Dose levels (IU m-2)
0.6 x 106 1
6 x 106 2
Reason for discontinuation
Early progression 3
Duration >6 weeks 17
Dose levels (IUm-2)
0.18 x 106 3
0.6 x 106 2
1.8 x 106 3
3 x 106 4
6 x 106 4
9 x 106 1
Reason for discontinuation
CVA infection 2
Toxicity 2
Progression 11
No change (patient refusal) 2
CVA = central venous access.
Feasibility
The patients quickly learned to manage the pump and to
replace the syringes and were discharged from the hospital
after 3-4 days of training. Slow rate continuous infusion for
a prolonged period of time via central venous access (CVA)
was frequently complicated by infusion interruption and
infection of the CVA. These complications mainly occurred
during the first period of the study, but decreased both in
number and severity as the study continued with better atten-
tion to technique and rigorous hygiene. A mechanical defect
of the portable pumps occurred only once during the total of
1,336 days of use. Especially during the first weeks of treat-
ment, interruption of the infusion occurred regularly and was
mainly due to mismanagement of the pump or to dislocation
of the insertion needle in the port of the CVA. Catheter
obstruction occurred in three cases and was associated with
thrombus formation at the tip of the CVA catheter in only
one case. In one case the infusion line was accidently cut in
half by the patient while trimming the garden hedge and in
another case the line was bitten through by the family pet.
For the patient the main discomfort consisted of the constant
confrontation with the disease, impaired activities of daily
living e.g. inability to take a shower, and impeded sex-life. In
no patient did this inconvenience prompt discontinuation of
the treatment.
Toxicity
Twenty patients who had continuous treatment with rIL-2
for >3 weeks were evaluable for toxicity. The duration of
treatment ranged from 21 to 126 days (median 50). In one of
the 22 entered patients the administration of rIL-2 was dis-
continued at <3 weeks because of toxicity, and in another
patient treatment was stopped prematurely because of the
occurrence of epidural metastasis.
The toxicity is shown in Tables Illa and b. In the four
cases of intrapatient dose escalation, the toxicity of the lower
dose level is scored in these tables. Toxicity was dose depen-
dent. In doses up to 3 x 106 IUm2 treatment was well
tolerated with mild side effects consisting of a mild flu-like
syndrome with malaise, fatigue, myalgia and low grade fever,
runny nose and erythema.
TableIlla Clinical toxicity ofcontinuous lowdose rIL-2 administered
for > 3 weeks
0.18 0.6 1.8 3 6 9
Symptom n=3 n=3 n=3 n=4 n=6 n=1
Fever
gr1 1 1 -
gr 2 b - 1 3 1
Chills
gr 1 2
gr 2 - -
Malaise/fatigue
gr I - 3 I1
gr 2 - - lb 1 6
gr 4 - - - - - 1
Myalgia/arthralgia
gr I - - 1 2 3 1
gr 2 - - - - 3
Nausea/vomiting
gr I - - 1 2 -
gr 2 - - 2 1
gr 3 - - - - 1
Runny nose - - 2 3 1
Erythema
gri 1 2 1
gr 2 - - - 1 1
Cheilitis
gr I 2 - 2 1
Hypotension
gr 2 id- -
Dose rIL-2 x 106 m-2 24 h-1. See also footnote at the end of Table
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Table IlIb Laboratory toxicity of continuous low dose rIL-2
administered for > 3 weeks
0.18 0.6 1.8 3 6 9
Symptom n=3 n=3 n=3 n=4 n=6 n=1
Haemoglobin (mmol 1-')
gr 1 1
gr 2 - 2 1
gr 3 - IC IC
Serum creatinine
gr 1 - id
gr 2 - c e
gr 4 - 1
Hepatic dysfunction
gri 1 -1
gr 2 - 1 1
gr 3 - - - - 2
CVA infectiona 2 1 2 4 7 1
Dose rIL-2 x 106 m2 24 h-'. TableIII shows theclinical(TableIla)
and laboratory (Table IlIb) toxicity ofcontinuous infusion ofvarious
doses ofrIL-2 according to the standard WHO criteria. For sideeffects
for which no standard WHO criteria are available, the toxicity score is
defined in the text. The haemoglobin level (mmol 1-) was compared
with the pretreatment level. ICVA infection = separate episodes of
positive blood cultures drawn from the central venous access. tTumour
related, crelated to tumour progression, drelated to concomitant use of
antihypertensive drugs, erelated to concomitant use of NSAID.
All patients with 6 x 106 IU m-2 24 h-' rIL-2 experienced
a pronounced flu-like syndrome with fatigue, myalgia, fever
up to 40°C and chills, nausea, vomiting and erythema. These
symptoms could be easily managed with simple supportive
measures. As indicated in Table II a total number of 11
cycles of 6 x 106 IU m-2 has been given. In three patients the
tretament was disrupted because of subjective toxicity con-
sisting ofgrade 2 malaise/fatigue and grade 2 fever. In two of
these patients who had received treatment for 5 and 27 days,
rIL-2 treatment was reinstituted at the same dose level. In
one patient the administration of rIL-2 was discontinued
after a further 10 days because of persistent fever with chills
and tumour progression while the other patient completed a
total 6 weeks course after restarting with only grade 1 toxi-
city. In the third patient treatment was stopped after 19 days
and not reinstituted because of possible rIL-2-related mental
exhaustion and depression.
Three patients were treated with 9 x 106 IU m2 24 h-'
rIL-2. Two patients experienced high grade fever up to 41°C
with chills, diffuse erythema and severe fatigue so that the
patient was bedridden. Treatment was discontinued after 3
and 4 days respectively. The third patient was treated for a
period of 6 weeks tolerating severe constitutional symptoms.
During the 6th week treatment was stopped because of acute
renal failure due to an acute interstitial nephritis which
resolved after haemodialysis and prednisone pulse therapy
(Diekman et al., 1992).
Interestingly, toxicity first because manifest within 3-5
days of treatment reached a peak after 2-3 weeks of treat-
ment and subsequently decreased despite continuation of the
rIL-2 treatment. In the three patients in whom the dose was
escalated from 3 x 106 to 6 x 106 IU m-2 24 h-' and in the
patient in whom the dose was escalated from 6 x 106 to
9 x 106 IU m-2 24 h-' only mild and transient increase in
toxicity was observed following the dose escalation. Apart
from the case of acute interstitial nephritis, organ dysfunc-
tion was clinically insignificant. Hepatic toxicity consisted of
elevation of the transaminases and alkaline phosphatase
without hyperbilirubinemia and occurred mostly during the
first 3 weeks of treatment and resolved despite continuation
of the rIL-2 treatment. Deterioration in renal function occur-
red in four patients and was related in individual patients to
the concomitant use of antihypertensive drugs (leading to
hypotension grade 2), non-steroidal anti-inflammatory drug
(NSAID), tumour progression or possible rIL-2 related-inter-
stitial nephritis. Cardiac and pulmonary dysfunction or signs
ofcapillary leakage were not observed. No changes in blood
pressure were observed, except in one patient who was con-
comitantly treated with antihypertensive drugs.
Skin toxicity consisted of diffuse or local erythema espec-
ially on palms or soles with subsequent desquamation, folli-
culitis on the trunk, occasionally subtle nail changes and
once localised bulla at the site of a peripheral vein access.
Oral and mucosal toxicity included cheilitis, change in taste
and dryness of oral and vaginal mucosa. Some patients
complained of emotional lability, impotence or decreased
libido. All these symptoms occurred at the higher dose levels,
were transient and of minor clinical importance.
The maximum tolerated dose for this type of treatment
was 6 x 106 IU m2 24 h-' and consisted of moderate
malaise, fatigue and fever up to 40°C.
Haematological effects
Except for the occurrence of anaemia in patients treated at
the highest dose, no haematological toxicity was encountered.
There were no significant changes in the lymphocyte and
granulocyte counts. However, there was a dose dependent
increase in the eosinophil counts as indicated in Figure la-f
and Table IV. At the higher dose levels the eosinophils
increased to approximately 20,000II-' making up two thirds
of the total white blood count. The eosinophil count reached
a peak around the second and third week of treatment and
decreased thereafter despite continuation of the rIL-2. Intra-
patient dose escalation, performed at the highest dose levels,
did not result in an additional increase or second peak in the
eosinophil count. No changes in the prothrombin time and
partial thromboplastin time were observed.
Immunological effects
The effects on the peripheral blood lymphocytes will be
discussed in detail in a separate paper. In summary, no
effects were seen in patients treated with 0.18 and 0.6 x 106
IUm-2 24 h'-. At the doses of 1.8 and 6 x 106IU
m224 h- the percentage of natural killer cells (NK) in-
creased to up to 75% of the peripheral blood lymphocytes.
In addition there was an increased number of cells expressing
CD25 (a chain IL-2 receptor), p75 (p chain IL-2 receptor),
and CD38. An increase in activated NK activity and in the
number of LAK precursor cells were observed. Furthermore,
antibody dependent cellular cytotoxicity (ADCC) was
enhanced. In contrast to the toxic and haematological effects
these immunological effects persisted throughout the entire
treatment period.
Infections
An infection of the CVA was defined as the presence of a
positive culture in blood drawn from the CVA in sympto-
matic as well as asymptomatic patients. In symptomatic
patients (fever >38°C and/or chills) and in some of the
asymptomatic patients peripheral blood cultures were obtain-
ed after a CVA infection had been documented. Sixteen
episodes of CVA infection were noted in 12 of 22 patients
(55%) (11 x Staphylococcus epidermidis, 1 x Pseudomonas
maltophilia, 1 x Bacillus, 1 x Klebsiella pneumoniae, 1 x Cor-
ynebacterium, 1 x Pseudomonas species). Nine of these CVA
infections occurred in the first eight patients treated. Infec-
tion was documented on average 25 days after the start of
the treatment (range 5-79). The presenting symptoms were
fever and chills (six) or local infection at the entry site (one),
nine infections were asymptomatic. The infection prompted
interruption of the rIL-2 treatment in six cases and in two
cases the CVA was removed. The infections were treated with
systemic antibiotic treatment through the CVA in ten cases.
As the study progressed the asymptomatic CVA infections
were considered as bacterial colonisation of the catheter and
were not treated in six cases.
In two of the total of six symptomatic episodes of CVA
infections peripheral blood cultures were positive (Staphy-
lococcus epidermidis, Bacillus). Two additional cases of CVA
infections occurred before the start of rIL-2 treatment.748 L.T. VLASVELD et al.
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Figure 1(a-f) Changes in the mean leukocyte, lymphocyte and eosinophil counts during treatment with rIL-2. At doses
> 1.8 x 106 IUm2 24 h-' a transient and significant rise in the eosinophil count occurred. -U- leucocytes, -0- eosinophils,
-0- lymphocyte.
Table IV Effects of continuous infusion of rIL-2 on eosinophil
count
Weeks Mean (cellspl`) s.d. P valuea
pre 210 138
1 290 117 n.s.
2 2980 3254 n.s.
3 4770 3885 n.s.
4 3270 2060 n.s.
5 3620 1729 n.s.
6 1530 1225 n.s.
Dose rIL-2: 1.8 x 106 IU m-224h-'. (n = 3)
Weeks Mean (cellsil-) s.d. P valuea
pre 230 236
1 340 466 n.s.
2 2680 1766 n.s.
3 5450 4767 n.s.
4 3230 1997 n.s.
5 3000 1901 n.s.
6 2050 616 <0.05
Dose rIL-2: 6 x 106 IU m-2 24 h-'. (n = 3).
The total eosinophil count was determined before and at weekly
intervals during treatment. aStudent (paired) t test, comparing the
pre-treatment with levels during treatment. s.d. = standard deviation.
Thrombotic complications
In 15 of the total of 18 episodes of CVA infection, and in
three cases of catheter obstruction without infection the
patency of the CVA was examined radiologically following
injection of contrast into the CVA. Evidence of thrombus
formation near the tip of the catheter was present in six cases
of CVA infection (5 x culture proven, 1 x strong clinical sus-
picion) and in one case of flow obstruction. In one of these
seven thrombotic events occlusion of the right brachioce-
phalic vein was present.
In six cases the thrombus resolved within 24-48 h follow-
ing low dose streptokinase infusion via the CVA. The venous
occlusion was successfully treated with systemic recombinant
tissue plasminogen activator (rTPA, Boehringer-Ingelheim,
Alkmaar, The Netherlands).
Responses
Thirteen patients could be evaluated for anti-tumour res-
ponse after at least 6 weeks of uninterrupted rIL-2 treatment.
Of the patients with malignant melanoma four had stable
disease, three had progression and one achieved partial
remission in a lymphnode metastasis. The partial remission
occurred with a dose at 1.8 x 106 IU m2 and was noted
within the first 3 weeks of treatment and lasted for 5 weeks.
In patients with renal cell cancer four patients had stable
disease and one had progression.
Discussion
This phase I study demonstrates that continuous self-admin-
istration of rIL-2 by a central venous access (CVA) for a
prolonged period of time on an out-patient basis is feasible.
The CVA-related complications such as infusion interruption
and CVA infection occurred especially during the first part of
the study and decreased both in number and severity as the
experience with this mode of treatment increased. In total 16,
mostly asymptomatic, infections of the central venous access
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were noted in 12 of the 22 patients treated with rIL-2 (55%)
and these data are in accordance with the observed high
incidence of line and systemic infections with predominantly
gram-positive cocci in patients treated with high-dose rIL-2
(Clark et al., 1990; Snydman et al., 1990). Although we did
not find a correlation between the incidence of infection and
the dose of rIL-2, the high infection rate may be related to
the known reversible effect of rIL-2 on the chemotaxis of the
neutrophils (Klempner et al., 1990) in combination with the
very slow infusion ofa protein-rich solution for a long period
of time. In approximately one third of the infections of the
central venous access, a thrombus at the tip of the catheter,
without clinical signs of flow obstruction, could be demon-
strated. The clinical significance of the thrombus formation is
at present uncertain. We decided to resolve the clots to avoid
occlusion of major veins. Local infusion of low-dose strepto-
kinase was successful in 100% of cases and was without
untoward effects.
The systemic toxicity in this phase I study was dose depen-
dent. No toxicity was observed up to a dose of 0.6 x 106 IU
m224h'. At doses of 1.8 x 106, 3x 106, and 6x 106IU
m 224h-', toxicity mainly consisted of easily manageable
constitutional symptoms without significant organ dysfunc-
tion or vascular leakage. At a dose of 9 x 106 IU m-2 24 h-l,
grade 4 toxicity occurred and prompted discontinuation of
treatment. Based on the presence of moderate fatigue/malaise
and fever <40'C the maximal tolerated dose was defined as
6 x 106 IU m-2 24 h-' for this mode of treatment on an out-
patient basis.
In most reported studies of continuous infusion of rIL-2,
the duration of administration varies from 1 to 5 days per
week. Depending on the treatment schedule the reported
maximal tolerated dose varies from 12 x 106 Um2 day-'
(Cetus) or 30 x 106 U m-2 day-' (Hoffmann-LaRoche) for
24 h infusion to 1 x 106 U m-2day-' (Hoffmann-LaRoche)
or 1,000 U kg-I h-I (t1 x 106 U m-2day-') (Cetus) for >1
week treatment (Creekmore et al., 1989; Kohler et al., 1989a;
Lotze et al., 1985; Perez et al., 1991) [see Note].
Rest days to recover from the toxicity are often needed. In
one of the earliest phase I studies, Lotze et al. gave rIL-2 by
continuous infusion for a period of 2-3 weeks at a maximal
tolerated dose of 1 x 106 U m-2 24h-' (Cetus) in two patients
(Lotze et al., 1985; 1987). In contrast to the findings in the
present study, the dose limiting toxicity consisted of vascular
leakage syndrome. Recently, two studies with prolonged
daily administrations of low dose rIL-2 (100iLgday-',
Glaxo/Biogen) as short term twice-daily intravenous infusion
or by subcutaneous injection for up to 80 days have been
reported with toxicity and immunological effects which are
comparable with those found by us (Marumo et al., 1989;
Stein et al., 1991). Interestingly, in the present study, signs of
toxicity appeared 3-5 days after initiation of treatment,
reached a peak at 2-3 weeks and decreased afterwards des-
pite continuation of the treatment. This phenomenon was
also observed by Lotze, but was not reported by Stein and
Marumo. This pattern was also noted with regard to the
changes in the eosinophil counts. The rIL-2 related toxicity
has been ascribed to the release of secondary cytokines such
as interferon and tumour necrosis factor (Gemlo et al., 1988).
The effect on the eosinophil count is considered to be the
result of the release ofinterleukin 5 (Macdonald et al., 1990).
In theory, several mechanisms may account for the transience
of the biological effects of rIL-2 such as the occurrence of
neutralising antibodies against rIL-2, down-regulation of one
or both components of the rIL-2 receptor, the generation or
up-regulation of inhibitory or negative feedback mechanisms,
or 'exhaustion' of the production or release of the secondary
cytokines. In view of the discrepancy between the transient
toxic and haematologic effects, and the observed persistent
immunological enhancement and upregulation of the IL-2
receptor, failure of the secondary cytokine mechanisms may
be the most likely.
The antitumour effect of the regimen used in this phase I
study consisted of an objective partial remission in a patient
with a lymphnode metastasis from a malignant melanoma.
This brief partial remission occurred in one of the three
patients who were treated with the well-tolerated dose of
1.8 x 106 IU m-2 24 h-'. Interestingly this tumour regression
occurred during the first 3 weeks of treatment which was
continued until a new lesion developed 5 weeks later. This
lesion was excised and the lymphnode metastasis disappeared
in the subsequent months. One year after the end of the
rIL-2 treatment the patient developed multiple brain metas-
tases. In the other two patients treated at this dose a minimal
tumour regression was seen during the first 3 weeks with
subsequent tumour progression despite further treatment.
Based on these observations phase II studies have been
initiated of intermittent continuous infusion for a period of 3
weeks at a dose of 1.8 x 106 IU m2 24 h- in patients with
malignant melanoma or renal cell cancer.
Note:
The specific activity and the unitage of the various rIL-2
compounds differ considerably: (Euro)Cetus (Proleukin'):
3 x 106 Umg' protein, Hoffmann-LaRoche (Teceleukin):
1.5 x I07 U mg ' protein, Glaxo/Biogen (Bioleukin): 1.7 x
106 Umg' protein (Stein et al., 1991) - 1 x 10' Umg-'
protein (Marumo et al., 1989). The interim reference reagent
(established in 1984) prepared from a human T cell line and
containing a nominal 500 Biological Response Modifiers Pro-
gram Units has been standardised in 1987 by the World
Health Organization with a defined potency of 100 Interna-
tional Units (IU = Biological Response Modification Project
Interim International Reference Standard Unit) (Gearing et
al., 1988). As a consequence one Cetus Unit equals six
International Units (Perez et al., 1991) and one Hoffmann-
LaRoche Unit equals one International Unit (Creekmore et
al., 1989).
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